Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report

Khan, Saqib Raza; Tariq, Muhammad; Fayyaz, Sidra Malik; Soomar, Salman Muhammad; Moosajee, Munira

doi:10.1016/j.lrr.2022.100315

Cited by 6 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to newly diagnosed ALL (dn ALL), the occurrence of high-risk cytogenetic and molecular features is higher in t-ALL. These features include BCR::ABL1 positivity, MLL rearrangements, and hyperdiploid (3,7,11,12). Several studies have also indicated that the incidence of BCR::ABL1 positivity is similar between these two types of leukemia (3,13).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Hu,

Li,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm-ALL). We report a case of a 51-year-old female patient who developed acute lymphoblastic leukemia 14 years after being diagnosed with diffuse large B-cell lymphoma (DLBCL). The patient was unresponsive to conventional chemotherapy for acute lymphoblastic leukemia (ALL) and achieved remission with a combination of sorafenib and decitabine based on the molecular biology characteristics of her B-ALL.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Previous reports indicate that patients with t-ALL can achieve a similar remission rate to dn ALL after conventional chemotherapy (1,7,11). However, t-ALL patients exhibit a significantly lower overall survival (OS) rate, with median OS ranging from 20 weeks to 13.6 months based on various studies (12).…”

Section: Discussionmentioning

confidence: 99%

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Hu,

Li,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Moreover, three clinical trials’ meta-analysis documented longer overall survival (OS) of patients with lenalidomide maintenance [ 73 ]. On the other hand, one is aware of the risk of secondary malignancies during long-term exposure to lenalidomide [ 74 ], especially the several recent reports that emerged about acute B-cell leukemia with diverse clinical courses and treatment outcomes [ 75 , 76 , 77 , 78 ].…”

Section: Immunomodulatory Drugs (Imids)mentioning

confidence: 99%

CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma

Barankiewicz

Salomon-Perzyński

Misiewicz-Krzemińska

et al. 2022

Cancers

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common hematological malignancy with a recurrent clinical course. The introduction of immunomodulatory drugs (IMiDs) was one of the milestones in MM therapy leading to a significant improvement in patients’ prognosis. Currently, IMiDs are the backbone of MM therapy in newly diagnosed and relapsed/refractory settings. It is now known that IMiDs exert their anti-myeloma activity mainly by binding cereblon (CRBN), the substrate receptor protein of the CRL4 E3 ubiquitin ligase (CRL4CRBN) complex. By binding CRBN, IMiDs alter its substrate specificity, leading to ubiquitination and proteasomal degradation of proteins essential for MM cell survival. Following the success of IMiDs, it is not surprising that the possibility of using the CRL4CRBN complex’s activity to treat MM is being further explored. In this review, we summarize the current state of knowledge about novel players in the MM therapeutic landscape, namely the CRBN E3 ligase modulators (CELMoDs), the next generation of IMiDs with broader biological activity. In addition, we discuss a new strategy of tailored proteolysis called proteolysis targeting chimeras (PROTACs) using the CRL4CRBN to degrade typically undruggable proteins, which may have relevance for the treatment of MM and other malignancies in the future.

show abstract

“…Имеются описания ВМДС и вторичных ОМЛ (ВОМЛ) после предшествующего острого лимфобластного лейкоза (ОЛЛ) [1][2][3], вторичного ОЛЛ (ВОЛЛ) [4,5], включая наблюдения ВОЛЛ после предшествующего лечения ОЛЛ и МДС [6,7].…”

Section: Introductionunclassified

Diagnosis of myelodysplastic syndromes after cytotoxic therapy for acute myeloid leukemia in the era of molecular research, difficulties in risk stratification and choice of therapy: The first domestic case report and literature review

Shirin,

Antipova,

Baranova

et al. 2023

Rossijskij bioterapevtičeskij žurnal

View full text Add to dashboard Cite

Diagnosis of secondary myeloid neoplasms (therapy-related myeloid neoplasms) associated with therapy of solid tumors, in most cases, is not associated with significant difficulties. The problem is the diagnosis of secondary myelodysplastic syndromes after the treatment of acute myeloid leukaemias. The complexity of early diagnosis of secondary myelodysplastic syndromes is due to the differentiation of this nosology and the early recurrence of previous acute myeloid leukemia and, as a result, the difficulties of prognosis and risk stratification for therapeutic management. The relevance of this problem is explained by the rare case reports. Making the diagnosis of secondary myelodysplastic syndrome, in our opinion, can be based on the absence of a connection of cancer cell clone with the first (previous) disease in a molecular study. In this publication, we describe the first domestic case report of myelodysplastic syndrome diagnosed after chemotherapy for acute myeloid leukemia, based on differences in cytomorphology, immunophenotyping and molecular research. we interpreted the prognosis as favorable and prescribed appropriate treatment.

show abstract

Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report

Cited by 6 publications

References 24 publications

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma

Diagnosis of myelodysplastic syndromes after cytotoxic therapy for acute myeloid leukemia in the era of molecular research, difficulties in risk stratification and choice of therapy: The first domestic case report and literature review

Contact Info

Product

Resources

About